BioStock article about the fully recruited phase 1b study and the interim data

Date: 2022-12-23

Alzinova's CEO Kristina Torfgård was interviewed about the latest news on the Companies vaccine candidate ALZ-101 against Alzheimer's disease.

Read the interview below (in Swedish).

https://www.biostock.se/2022/12/alzinova-om-interimsresultaten-och-den-nu-fullrekryterade-fas-ib-studien/